KalVista Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with si...
Latest News
5 months ago · businesswire.com
Chiesi Group Completes Acquisition of KalVista PharmaceuticalsPARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transac.
6 months ago · zacks.com
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
6 months ago · businesswire.com
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary AngioedemaFRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl.
7 months ago · businesswire.com
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceFRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m. EST A live audio webcast of the presentation will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of.
7 months ago · seekingalpha.com
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case AliveKalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind. Looking ahead, Ekterly's potential pediatric expansion into ages 2 to 11 could add meaningful upside.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove KALV